Adjuvant-protein conjugate vaccine with built-in TLR7 agonist on S1 induces potent immunity against SARS-CoV-2 and variants of concern

RY Zhang, SH Zhou, CB He, J Wang… - ACS Infectious …, 2022 - ACS Publications
With the global pandemic of the new coronavirus disease (COVID-19), a safe, effective, and
affordable mass-produced vaccine remains the current focus of research. Herein, we …
被引用次数：13 相关文章

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.

RY Zhang, SH Zhou, CB He, J Wang, Y Wen… - ACS Infectious …, 2022 - europepmc.org
With the global pandemic of the new coronavirus disease (COVID-19), a safe, effective, and
affordable mass-produced vaccine remains the current focus of research. Herein, we …

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern

RY Zhang, SH Zhou, CB He, J Wang… - ACS infectious …, 2022 - pubmed.ncbi.nlm.nih.gov
With the global pandemic of the new coronavirus disease (COVID-19), a safe, effective, and
affordable mass-produced vaccine remains the current focus of research. Herein, we …

[引用][C] Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV‑2 and Variants of Concern

RY Zhang, SH Zhou, CB He, J Wang, Y Wen, RR Feng… - 2022 - europepmc.org
With the global pandemic of the new coronavirus disease (COVID-19), a safe, effective, and
affordable massproduced vaccine remains the current focus of research. Herein, we …